Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
140 USD | -1.28% | -1.68% | +1.57% |
May. 21 | Declaration of Voting Results by Quest Diagnostics Incorporated | CI |
May. 16 | Quest Diagnostics Elects Robert B. Carte to Board of Directors | CI |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company is in debt and has limited leeway for investment
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.57% | 15.56B | A- | ||
+16.49% | 82.59B | C+ | ||
-29.52% | 69.86B | B- | ||
0.00% | 26.5B | C+ | ||
-13.29% | 16.61B | B | ||
+3.95% | 17.29B | A- | ||
+71.63% | 13.2B | C- | ||
+1.53% | 12.75B | B- | ||
+70.68% | 12.6B | C+ | ||
+8.30% | 12.19B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DGX Stock
- Ratings Quest Diagnostics Incorporated